{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T02:43:08Z","timestamp":1772678588293,"version":"3.50.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000182","name":"US Army Medical Research and Materiel Command","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000182","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010203","name":"Walter Reed Army Institute of Research","doi-asserted-by":"publisher","award":["W81XWH-12-D-0044-0002"],"award-info":[{"award-number":["W81XWH-12-D-0044-0002"]}],"id":[{"id":"10.13039\/100010203","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cherokee Nation Technology Solutions LLC","award":["CNTSSUNY001"],"award-info":[{"award-number":["CNTSSUNY001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Dengue is a global health problem requiring an effective, safe dengue vaccine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We report the results of a phase II, randomized, open-label, single-center trial in adults aged 18 to 45 years in the United States designed to explore the effects of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD-TDV, Dengvaxia) when administered on its designated schedule (months 0, 6, and 12) or on an accelerated dosing schedule (months 0, 2, and 6) and\/or given before, or concomitantly with, a vaccine against Japanese encephalitis (JE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Based on dengue virus serotype-specific neutralizing antibody (NAb), the accelerated dosing schedule was comparable to the 0, 6, and 12-month schedule. Giving JE vaccine concurrently with CYD-TDV did not result in an increase in overall NAb titers. Immunophenotyping of peripheral blood mononuclear cells revealed an increase in activated CD8+ T cells after CYD-TDV vaccination, a phenomenon that was greatest for the JE vaccine primed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We conclude that an accelerated dosing schedule of CYD-TDV results in essentially equivalent dengue serotype-specific NAb titers as the currently used schedule, and there may be an early benefit in antibody titers and activated CD8+ T cells by the administration of the JE vaccine before CYD-TDV vaccination.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiz592","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T20:11:34Z","timestamp":1573762294000},"page":"1057-1069","source":"Crossref","is-referenced-by-count":8,"title":["The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States"],"prefix":"10.1093","volume":"221","author":[{"given":"Aaron","family":"Glass","sequence":"first","affiliation":[{"name":"Institute for Global Health and Translational Sciences, Microbiology and Immunology, and Public Health, State University of New York, Upstate Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Polhemus","sequence":"additional","affiliation":[{"name":"Institute for Global Health and Translational Sciences, Microbiology and Immunology, and Public Health, State University of New York, Upstate Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongliang","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute for Global Health and Translational Sciences, Microbiology and Immunology, and Public Health, State University of New York, Upstate Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G","family":"Jarman","sequence":"additional","affiliation":[{"name":"Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J","family":"Thomas","sequence":"additional","affiliation":[{"name":"Institute for Global Health and Translational Sciences, Microbiology and Immunology, and Public Health, State University of New York, Upstate Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Friberg","sequence":"additional","affiliation":[{"name":"Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R","family":"Currier","sequence":"additional","affiliation":[{"name":"Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Bonaparte","sequence":"additional","affiliation":[{"name":"Global Clinical Immunology Department, Sanofi Pasteur, Swiftwater, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"De La Barra","sequence":"additional","affiliation":[{"name":"Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F","family":"Princiotta","sequence":"additional","affiliation":[{"name":"Institute for Global Health and Translational Sciences, Microbiology and Immunology, and Public Health, State University of New York, Upstate Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Abbott","sequence":"additional","affiliation":[{"name":"Institute for Global Health and Translational Sciences, Microbiology and Immunology, and Public Health, State University of New York, Upstate Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Cuzzo","sequence":"additional","affiliation":[{"name":"Institute for Global Health and Translational Sciences, Microbiology and Immunology, and Public Health, State University of New York, Upstate Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tifany","family":"Machabert","sequence":"additional","affiliation":[{"name":"Global Clinical Sciences, Sanofi Pasteur, Marcy l\u2019Etoile, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saranya","family":"Sridhar","sequence":"additional","affiliation":[{"name":"Global Clinical Sciences, Sanofi Pasteur, Marcy l\u2019Etoile, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy P","family":"Endy","sequence":"additional","affiliation":[{"name":"Institute for Global Health and Translational Sciences, Microbiology and Immunology, and Public Health, State University of New York, Upstate Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"key":"2020120619135060600_CIT0001","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1473-3099(16)00146-8","article-title":"The global economic burden of dengue: a systematic analysis","volume":"16","author":"Shepard","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2020120619135060600_CIT0002","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1473-3099(16)00026-8","article-title":"The global burden of dengue: an analysis from the Global Burden of Disease Study 2013","volume":"16","author":"Stanaway","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2020120619135060600_CIT0003","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"2020120619135060600_CIT0004","doi-asserted-by":"crossref","first-page":"e1760","DOI":"10.1371\/journal.pntd.0001760","article-title":"Refining the global spatial limits of dengue virus transmission by evidence-based consensus","volume":"6","author":"Brady","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2020120619135060600_CIT0005","volume-title":"Global","author":"World Health Organization","year":"2012"},{"key":"2020120619135060600_CIT0006","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrmicro1690","article-title":"Prospects for a dengue virus vaccine","volume":"5","author":"Whitehead","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"2020120619135060600_CIT0007","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"2020120619135060600_CIT0008","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"key":"2020120619135060600_CIT0009","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"key":"2020120619135060600_CIT0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"2020120619135060600_CIT0011","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"2020120619135060600_CIT0012","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"2020120619135060600_CIT0013","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.4161\/21645515.2014.972131","article-title":"Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-na\u00efve adults in Mexico","volume":"10","author":"Dayan","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2020120619135060600_CIT0014","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4269\/ajtmh.2011.10-0436","article-title":"Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans","volume":"85","author":"Qiao","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2020120619135060600_CIT0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1473-3099(18)30023-9","article-title":"The dengue vaccine dilemma","volume":"18","author":"The Lancet Infectious Diseases","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2020120619135060600_CIT0016","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"2020120619135060600_CIT0017","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.aaf9590","article-title":"Benefits and risks of the Sanofi-Pasteur dengue vaccine: modeling optimal deployment","volume":"353","author":"Ferguson","year":"2016","journal-title":"Science"},{"key":"2020120619135060600_CIT0018","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.qco.0000433310.28771.cc","article-title":"Current issues in dengue vaccination","volume":"26","author":"Thomas","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"2020120619135060600_CIT0019","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4269\/ajtmh.2012.12-0361","article-title":"A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults","volume":"88","author":"Thomas","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2020120619135060600_CIT0020","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","article-title":"Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2020120619135060600_CIT0021","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.inf.0000109289.55856.27","article-title":"Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children","volume":"23","author":"Sabchareon","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"2020120619135060600_CIT0022","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4269\/ajtmh.2002.66.264","article-title":"Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses","volume":"66","author":"Sabchareon","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"2020120619135060600_CIT0023","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"2020120619135060600_CIT0024","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.4269\/ajtmh.13-0304","article-title":"Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil","volume":"89","author":"Dayan","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2020120619135060600_CIT0025","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1016\/j.vaccine.2011.08.117","article-title":"Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO(\u00ae)","volume":"29","author":"Schuller","year":"2011","journal-title":"Vaccine"},{"key":"2020120619135060600_CIT0026","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"key":"2020120619135060600_CIT0027","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/infdis\/jiu573","article-title":"Prolonged proinflammatory cytokine production in monocytes modulated by interleukin 10 after influenza vaccination in older adults","volume":"211","author":"Mohanty","year":"2015","journal-title":"J Infect Dis"},{"key":"2020120619135060600_CIT0028","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1086\/382280","article-title":"Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand","volume":"189","author":"Endy","year":"2004","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz592\/31270385\/jiz592.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/7\/1057\/32913659\/jiz592.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/7\/1057\/32913659\/jiz592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T01:54:30Z","timestamp":1607306070000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/221\/7\/1057\/5637716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,11,22]]},"published-print":{"date-parts":[[2020,3,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz592","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4,1]]},"published":{"date-parts":[[2019,11,22]]}}}